Form 4: Director Alan Grujic Boosts GTHP Stake Through Conversions and Financing

GUIDED THERAPEUTICS Director Alan Grujic increased his beneficial ownership of common stock and warrants through dividend payments, preferred stock conversion, and private financing.

Summary

• Alan Grujic, a Director of GUIDED THERAPEUTICS INC (GTHP), reported several transactions increasing his beneficial ownership.
• On August 21, 2025, Mr. Grujic acquired 17,408 shares of common stock as payment for accrued dividends on his Series E preferred stock, at a conversion price of $0.2298 per share.
• Also on August 21, 2025, he converted 50 shares of Series E preferred stock, with a stated value of $1,000 each, into 200,000 shares of common stock at a conversion price of $0.25 per share.
• On August 29, 2025, as part of the Company's Tranche 4 Private Financing, Mr. Grujic exchanged a $25,000 note payable and $2,379.45 in accrued interest for 152,108 units.
• Each unit consisted of one share of common stock and one warrant to purchase common stock, with the warrants immediately exercisable at $0.25 per share and expiring on August 28, 2029.
• Following these transactions, Mr. Grujic beneficially owns 1,817,541 shares of common stock and 177,108 warrants.

Sentiment

Score: 7

Explanation: The transactions reflect significant insider buying and conversion of debt/preferred equity to common equity, which is generally a positive signal of management confidence in the company's future. The reduction of debt through equity exchange is also a positive for the company's financial health.

Positives

• Increased insider ownership by a director signals confidence in the company's future prospects.
• Conversion of preferred stock to common stock simplifies the capital structure and demonstrates a long-term commitment.
• Exchange of a note payable and accrued interest for equity reduces the company's debt burden and strengthens its balance sheet.

Risks

• The private financing, which involved converting a note payable to equity, could indicate the company's need for capital, potentially signaling liquidity challenges or a desire to reduce debt obligations.

Future Outlook

The warrants acquired by Mr. Grujic are immediately exercisable and will expire on August 28, 2029, providing a future opportunity for further equity conversion at a fixed price.

Related Party Transactions

• Director Alan Grujic engaged in a transaction with GUIDED THERAPEUTICS INC, exchanging a $25,000 note payable and $2,379.45 in accrued interest for common stock and warrants as part of the Tranche 4 Private Financing.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management's belief in the company's value.
• Creditors benefit from the conversion of a note payable into equity, which reduces the company's outstanding debt obligations.

Key Dates

Recommendation

The insider buying by a director is a positive signal, indicating confidence in the company's prospects. However, a Form 4 filing primarily discloses transactions and does not provide comprehensive financial performance data or strategic updates necessary for a strong buy or sell recommendation. Investors should consider this insider activity alongside broader financial analysis and market conditions.

Keywords

GTHP, GUIDED THERAPEUTICS, Form 4, Insider Trading, Stock Acquisition, Warrants, Preferred Stock Conversion, Private Financing, Director Ownership